Supported by grants from Programme Hospitalier de Recherche Clinique National (AOM05157), Association François Aupetit, Délégation Inter-régionale de la Recherche Clinique Ile de France-Assistance Publique Hôpitaux de Paris (AP-HP), Ligue contre le Cancer, Fonds de Recherche de la Société Nationale Française de Gastro-entérologie, and Institut de Recherche sur les Maladies de l'Appareil Digestif (IRMAD).
Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease†
Article first published online: 23 JAN 2012
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 11, pages 2063–2071, November 2012
How to Cite
Sokol, H., Beaugerie, L., Maynadié, M., Laharie, D., Dupas, J.-L., Flourié, B., Lerebours, E., Peyrin-Biroulet, L., Allez, M., Simon, T., Carrat, F., Brousse, N. and for the CESAME Study Group (2012), Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis, 18: 2063–2071. doi: 10.1002/ibd.22889
- Issue published online: 15 OCT 2012
- Article first published online: 23 JAN 2012
- Manuscript Accepted: 22 DEC 2011
- Manuscript Received: 16 DEC 2011
- CESAME study;
- primary intestinal lymphomas;
- inflammatory bowel disease;
It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders (PILD). We assessed this risk in the CESAME French nationwide prospective observational cohort.
In all, 680 gastroenterologists enrolled 19,486 patients with IBD (Crohn's disease in 60.3%) from May 2004 to June 2005. Follow-up ended on 31 December 2007. Available biopsy samples and surgical specimens from patients with PILD (n = 14) were centralized for review. The reference incidence of PILD in the general population was obtained from the Côte d'Or registry and was used as a comparator to assess the standardized incidence ratio (SIR). The influence of thiopurine exposure was explored in a nested case-control study.
In the CESAME population the crude incidence of PILD was 0.12/1000 patient-years, with a corresponding SIR of 17.51 (95% confidence interval [CI], 6.43–38.11; P < 0.0001). The risk was highest in patients exposed to thiopurines (SIR 49.52, 95% CI 13.49–126.8; P < 0.0001), while it did not reach statistical significance in patients naïve to thiopurines (SIR 4.83, 95% CI, 0.12–26.91; P = 0.37). The odds ratio associated with ongoing thiopurine exposure (vs. naïve) was 2.97 (95% CI, 0.30–infinity; P = 0.38). All 14 cases of PILD were non-Hodgkin's B-cell LD, 78.6% occurred in males, 85.7% arose in IBD lesions, and 45.5% were Epstein–Barr virus-positive. Eleven cases occurred in patients with Crohn's disease. Mean (SD) age at PILD diagnosis was 55.1 (5.6) years and the median time since IBD onset was 8.0 years (interquartile range, 3.0–15.8).
Patients with IBD have an increased risk of developing PILD. (Inflamm Bowel Dis 2012;)